AgingResearch.NewsJoin free

Phase 2Completed

Ruxolitinib for Premalignant Breast Disease (TBCRC042)

TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions

Sponsor
Julie Nangia (Academic or other)
Enrolment
84 enrolled
Conditions
Ductal Carcinoma In Situ; Atypical Lobular Hyperplasia; Atypical Ductal Hyperplasia; Lobular Carcinoma In Situ
Interventions
Ruxolitinib; Placebo (for Ruxolitinib)
Ages
adults, older adults
Registry
NCT02928978

Full record on ClinicalTrials.gov

From the registry

This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.

Primary outcomes

  • Change in Percent of Apoptotic Cells

History

  1. Results first posted

  2. Last registry update

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered